Psoriatic Arthritis: Joint Disease and Skin Involvement

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects both the joints and the skin, arising in a subset of individuals with psoriasis. It sits within the broader category of spondyloarthropathies and can cause progressive joint damage if not identified and treated early. This page covers the disease definition, the underlying inflammatory mechanisms, the clinical patterns that present in practice, and the criteria used to distinguish PsA from other forms of inflammatory arthritis.

Definition and scope

Psoriatic arthritis is classified by the American College of Rheumatology (ACR) as an inflammatory arthritis associated with psoriasis, a chronic skin condition affecting an estimated 2–3% of the US population (National Psoriasis Foundation). Among people with psoriasis, approximately 30% develop psoriatic arthritis at some point, according to data published by the National Psoriasis Foundation. The condition is seronegative, meaning rheumatoid factor is typically absent, which distinguishes it from rheumatoid arthritis and places it in a distinct diagnostic and therapeutic category.

PsA is recognized as a systemic inflammatory disease with musculoskeletal, cutaneous, and entheseal (tendon and ligament insertion) involvement. The Classification Criteria for Psoriatic Arthritis (CASPAR), developed through an international collaborative study and published in Arthritis & Rheumatism in 2006, remain the standard reference framework for classification. CASPAR criteria assign weighted scores across five domains: psoriatic skin or nail disease, negative rheumatoid factor, dactylitis, juxta-articular new bone formation on imaging, and family history of psoriasis. A score of 3 or higher from these domains classifies the condition as PsA.

The condition falls under the broader regulatory and care frameworks governing rheumatic disease in the United States. For an overview of how federal oversight, drug approval pathways, and clinical guidelines apply to rheumatologic practice, the regulatory context for rheumatology provides relevant framing on agency roles including the FDA and ACR guideline processes.

How it works

The pathophysiology of psoriatic arthritis involves dysregulation of the innate and adaptive immune systems, resulting in chronic synovial inflammation and bone remodeling. Key cytokines driving this process include tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23). Genetic susceptibility is strongly linked to HLA-B27 and HLA-Cw6 alleles, though neither is diagnostic in isolation. For a detailed discussion of genetic marker testing in rheumatic disease, see the page on HLA-B27 and genetic markers.

The inflammatory cascade in PsA targets the synovium (joint lining), entheses (insertion points of tendons and ligaments), and the skin. Unlike rheumatoid arthritis, PsA can produce a pattern of bone erosion alongside paradoxical new bone formation (periostitis), leading to the distinctive "pencil-in-cup" deformity visible on plain radiograph in severe cases.

Enthesitis—inflammation at tendon or ligament insertion points—is a hallmark feature absent from rheumatoid arthritis and plays a central role in distinguishing PsA from other inflammatory joint diseases. The Achilles tendon and plantar fascia insertions are the 2 most commonly affected entheseal sites in clinical assessment.

Common scenarios

Psoriatic arthritis presents across five recognized clinical subtypes, each with distinct joint involvement patterns:

  1. Asymmetric oligoarthritis — involvement of fewer than 5 joints, often affecting large joints of the lower extremity; the most common subtype at disease onset
  2. Symmetric polyarthritis — resembles rheumatoid arthritis with bilateral small joint involvement; can be misclassified without serology and imaging
  3. Distal interphalangeal (DIP) predominant — characteristic involvement of the terminal finger and toe joints, often with associated nail pitting or onycholysis
  4. Spondylitis — axial involvement affecting the spine and sacroiliac joints, overlapping with ankylosing spondylitis; relevant comparison is discussed on the ankylosing spondylitis page
  5. Arthritis mutilans — the most destructive subtype, characterized by osteolysis and severe joint deformity; occurs in fewer than 5% of PsA patients

Nail disease, present in up to 80% of PsA patients according to the National Psoriasis Foundation, is a particularly useful clinical marker because DIP joint inflammation and nail psoriasis share a common entheseal attachment at the extensor tendon insertion.

Dactylitis ("sausage digits"), diffuse swelling of an entire finger or toe, occurs in approximately 40–50% of PsA patients and serves as one of the CASPAR scoring criteria. Its presence narrows the differential diagnosis significantly compared to other seronegative arthropathies.

Inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are elevated in active disease but are nonspecific. Imaging with musculoskeletal ultrasound or MRI improves detection of subclinical synovitis and enthesitis beyond what plain radiographs reveal. A full breakdown of imaging modalities used in rheumatic disease appears at imaging in rheumatic disease.

Decision boundaries

Distinguishing PsA from other forms of arthritis requires structured evaluation across clinical, serological, and imaging domains. Three key comparisons define the decision boundaries in practice:

PsA vs. Rheumatoid Arthritis (RA): Both can present as symmetric polyarthritis, but PsA is seronegative (negative RF and typically negative anti-CCP), involves DIP joints (spared in RA), and produces enthesitis. The presence of psoriatic skin or nail changes is the most decisive differentiating feature. See anti-CCP and rheumatoid factor testing for serological comparison.

PsA vs. Gout: Both can cause acute monoarthritis with significant swelling. Gout is identified by elevated serum uric acid and sodium urate crystal analysis on joint aspiration, while PsA requires CASPAR-based clinical scoring. Joint aspiration (joint aspiration) remains the definitive tool when crystal arthropathy is suspected.

PsA vs. Osteoarthritis (OA): DIP joint involvement overlaps between PsA and OA, but inflammatory markers, imaging evidence of erosion, and skin/nail findings differentiate them. The comparison of osteoarthritis with inflammatory arthritis is covered in detail at osteoarthritis vs. inflammatory arthritis.

Treatment decisions in PsA follow ACR guidelines, with NSAIDs as first-line agents for mild disease (NSAIDs in pain management), advancing to conventional DMARDs such as methotrexate, and then to biologics targeting TNF-α, IL-17, or IL-23 for moderate-to-severe disease (biologic therapies). The FDA has approved 11 biologic or targeted synthetic agents for PsA as of the most recent ACR guideline update, reflecting the breadth of therapeutic options now available. For a full overview of rheumatic disease management and care resources, the rheumatology authority index provides access to the complete topic framework.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)